Form 4: Neuphoria Director Alan Fisher Granted RSUs

Neuphoria Therapeutics Inc. Director Alan Fisher received a grant of 17,073 Restricted Stock Units as part of the company's annual remuneration policy.

Summary

• Alan Fisher, a Director of Neuphoria Therapeutics Inc. (NEUP), was granted 17,073 Restricted Stock Units (RSUs) on January 20, 2026.
• This grant is part of the company's Board of Directors annual remuneration policy.
• Each RSU represents a contingent right to receive one share of common stock.
• The RSUs will fully vest subject to continuous service until the day prior to the company's next annual shareholder meeting (expected by December 15, 2026) or the effective date of a Change in Control.
• Following this transaction, Alan Fisher beneficially owns 30,731 derivative securities (RSUs).

Sentiment

Score: 7

Explanation: A routine RSU grant to a director is generally positive as it aligns interests, but it's a standard compensation event rather than a significant operational or financial breakthrough. It reflects normal corporate governance and compensation practices.

Positives

• The grant of 17,073 Restricted Stock Units (RSUs) to Director Alan Fisher aligns his interests with long-term shareholder value.
• The RSUs are part of the company's annual remuneration policy, indicating a structured and consistent approach to executive compensation.

Risks

• The ultimate value of the RSUs is contingent on the future market price of Neuphoria Therapeutics Inc. common stock.
• Vesting of the RSUs is subject to continuous service, meaning the units could be forfeited if the reporting person's service is terminated before the vesting conditions are met.

Future Outlook

The Restricted Stock Units are expected to fully vest by the day prior to the company's next annual shareholder meeting, which is anticipated to occur no later than December 15, 2026, or upon the effective date of a Change in Control of the company.

Management Comments

• The grant of Restricted Stock Units is pursuant to the Company's Board of Directors annual remuneration policy.

Industry Context

The grant of Restricted Stock Units to a director is a common practice in the biotechnology and pharmaceutical industry for executive compensation. This method aims to align management incentives with long-term company performance and shareholder interests, fostering retention and commitment.

Comparison to Industry Standards

• Granting RSUs as part of an annual remuneration policy is a standard practice across many publicly traded companies, particularly in growth-oriented sectors like biotech, to retain and incentivize key personnel.
• Companies such as Moderna (MRNA) and BioNTech (BNTX) frequently utilize RSU grants as a component of their executive and director compensation packages to foster long-term commitment and performance alignment.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased alignment of the director's interests with long-term company performance and shareholder value creation.
• Employees: May signal a stable and structured compensation framework for key personnel, potentially boosting morale and retention.

Next Steps

• The company's next annual shareholder meeting is expected to occur no later than December 15, 2026, which is a key date for the vesting of the granted RSUs.

Key Dates

Recommendation

This Form 4 reports a standard grant of Restricted Stock Units to a director as part of the company's annual remuneration policy. While it aligns the director's interests with long-term shareholder value, it does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing does not present new catalysts for significant price movement.

Keywords

Neuphoria Therapeutics, NEUP, Alan Fisher, Director, Restricted Stock Units, RSU, insider transaction, executive compensation, Form 4, beneficial ownership